{"id":"W4295297459","doi":"10.1016/j.jtho.2022.08.018","title":"Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; EMD Serono; Teijin Pharma; Daiichi-Sankyo; G1 Therapeutics; BeiGene; Mirati Therapeutics; Bristol-Myers Squibb; Society for Academic Continuing Medical Education; Johnson and Johnson; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; Takeda Pharmaceutical Company; AbbVie; Merck; Yuhan; Merck KGaA; Daiichi Sankyo Europe; Bayer; Gilead Sciences; Roche; Novartis; GlaxoSmithKline Japan; Sanofi; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Alectinib; Ceritinib; Medicine; Crizotinib; Internal medicine; ALK inhibitor; Anaplastic lymphoma kinase; Lung cancer; Gastroenterology; Oncology; Clinical endpoint; Adverse effect; Confidence interval; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001107474,0.0006526377,0.000891373,0.0001769252,0.0002294627,0.0007795755,0.0004303078,0.0005799696,0.001716483],"category_scores_gemma":[0.0006601526,0.000238835,0.0009329035,0.0001993832,0.0002724184,0.0003410254,0.0001984461,0.001364537,0.0003532941],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006089224,"about_ca_system_score_gemma":0.0007220939,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005854038,"about_ca_topic_score_gemma":0.002539633,"domain_scores_codex":[0.9997548,0.0001047672,0.0000192171,0.00005211479,0.00002743137,0.00004171248],"domain_scores_gemma":[0.9996498,0.00006850045,0.0001140673,0.00002518139,0.00002487129,0.000117553],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.789571,0.01099439,0.05356833,0.001170858,0.004217664,0.000339637,0.000280229,0.002432995,0.02976253,0.0001750848,0.003582142,0.1039051],"study_design_scores_gemma":[0.5682607,0.2468244,0.1655805,0.0001961024,0.003698739,0.0008668849,0.0001255303,0.002807905,0.005558436,0.0002340138,0.005780341,0.00006641745],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951711,0.002666312,0.00009301375,0.000210867,0.00006121897,0.0002142237,0.000411715,0.00003121462,0.001140203],"genre_scores_gemma":[0.9966167,0.0007605242,0.0001990195,0.0002692738,0.0001110242,0.0001780014,0.00109408,0.000004049205,0.0007673952],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001716483,"threshold_uncertainty_score":0.005856931,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0152491628014952,"score_gpt":0.4381507330189958,"score_spread":0.4229015702175006,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}